metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1			-
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1			-
	nivolumab alone vs. Standard of Care (SoC)	1			-
	pembrolizumab alone vs. Standard of Care (SoC)	1			-
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative
versus durvalumab alone
	durvalumab plus tremelimumab vs. durvalumab alone	1			-
versus tremelimumab
	durvalumab plus tremelimumab vs. tremelimumab	1			-
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1			-